Literature DB >> 27654608

Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment.

Bradley D Stein1, Mark Sorbero2, Andrew W Dick3, Rosalie Liccardo Pacula4, Rachel M Burns2, Adam J Gordon5.   

Abstract

Entities:  

Year:  2016        PMID： 27654608      PMCID： PMC5257276          DOI： 10.1001/jama.2016.10542

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

Authors:  David A Fiellin; Richard S Schottenfeld; Christopher J Cutter; Brent A Moore; Declan T Barry; Patrick G O'Connor
Journal:  JAMA Intern Med       Date:  2014-12       Impact factor: 21.873

2.  The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.

Authors:  James E Egan; Paul Casadonte; Tracy Gartenmann; Judith Martin; Elinore F McCance-Katz; Julie Netherland; John A Renner; Linda Weiss; Andrew J Saxon; David A Fiellin
Journal:  J Gen Intern Med       Date:  2010-05-11       Impact factor: 5.128

3.  Factors affecting willingness to provide buprenorphine treatment.

Authors:  Julie Netherland; Michael Botsko; James E Egan; Andrew J Saxon; Chinazo O Cunningham; Ruth Finkelstein; Mark N Gourevitch; John A Renner; Nancy Sohler; Lynn E Sullivan; Linda Weiss; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2008-08-20

4.  Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.

Authors:  Wei-Hsuan Lo-Ciganic; Walid F Gellad; Adam J Gordon; Gerald Cochran; Michael A Zemaitis; Terri Cathers; David Kelley; Julie M Donohue
Journal:  Addiction       Date:  2016-01-30       Impact factor: 6.526
  4 in total
  44 in total

1.  Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018.

Authors:  Yulin Hswen; Amanda Zhang; John S Brownstein
Journal:  Prev Med       Date:  2020-04-27       Impact factor: 4.018

2.  Geographic location of buprenorphine-waivered physicians and integration with health systems.

Authors:  Brendan Saloner; LeeKai Lin; Kosali Simon
Journal:  J Subst Abuse Treat       Date:  2020-05-12

3.  Ending the Opioid Epidemic by Changing the Culture.

Authors:  Lloyd I Sederer; Leslie A Marino
Journal:  Psychiatr Q       Date:  2018-12

4.  County-level access to opioid use disorder medications in medicare Part D (2010-2015).

Authors:  Amanda J Abraham; Grace Bagwell Adams; Ashley C Bradford; William D Bradford
Journal:  Health Serv Res       Date:  2019-01-21       Impact factor: 3.402

5.  Development of a Cascade of Care for responding to the opioid epidemic.

Authors:  Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Frances R Levin; Mark Olfson
Journal:  Am J Drug Alcohol Abuse       Date:  2019-01-24       Impact factor: 3.829

6.  DSM-5 substance use disorders among adult primary care patients: Results from a multisite study.

Authors:  Li-Tzy Wu; Jennifer McNeely; Geetha A Subramaniam; Kathleen T Brady; Gaurav Sharma; Paul VanVeldhuisen; He Zhu; Robert P Schwartz
Journal:  Drug Alcohol Depend       Date:  2017-07-13       Impact factor: 4.492

7.  Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study.

Authors:  Todd Molfenter; Maureen Fitzgerald; Nora Jacobson; Dennis McCarty; Andrew Quanbeck; Mark Zehner
Journal:  J Psychoactive Drugs       Date:  2019-02-07

8.  Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use.

Authors:  Nora Jacobson; Julie Horst; Liam Wilcox-Warren; Alex Toy; Hannah K Knudsen; Randy Brown; Eric Haram; Lynn Madden; Todd Molfenter
Journal:  J Behav Health Serv Res       Date:  2020-10       Impact factor: 1.505

9.  Association Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural Location, and Neonatal Abstinence Syndrome.

Authors:  Stephen W Patrick; Laura J Faherty; Andrew W Dick; Theresa A Scott; Judith Dudley; Bradley D Stein
Journal:  JAMA       Date:  2019-01-29       Impact factor: 56.272

10.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Authors:  Rebecca L Haffajee; Amy S B Bohnert; Pooja A Lagisetty
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.